Zhang Wei, Wang Jian, Liu Shu-Juan, Hua Wei, Xin Xiao-Yan
Department of Gynecology and Obstetrics, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Acta Obstet Gynecol Scand. 2009;88(5):521-7. doi: 10.1080/00016340902835927.
Aurora-A, a novel member of the serine/threonine kinase family, has been reported to be correlated with tumorigenesis. Our aim was to investigate whether Aurora-A expression correlates with clinicopathologic factors and prognosis of cervical carcinoma patients.
DESIGN/SETTING: Retrospective study.
Seventy-four cervical carcinoma patients, between 1996 and 2002.
Reverse transcription-polymerase chain reaction and Western blot assays were performed to detect the expression of Aurora-A gene in cervical carcinoma cells and paired cancerous and corresponding noncancerous tissues from 74 cervical carcinoma patients. The expression of Aurora-A protein in tissues was also determined by immunohistochemistry. The relationships of Aurora-A expression with clinical factors and prognosis of patients were evaluated by statistical analysis.
The expression of Aurora-A mRNA and protein was significantly higher in cervical carcinoma cells than in normal cervical epithelial cell (p<0.05). The expression of Aurora-A mRNA in cancerous tissues was significantly higher than that in corresponding noncancerous tissues (p<0.001). The expression of Aurora-A protein was also increased in tumor tissues by immunochemistry. Aurora-A transcript expression was correlated with FIGO stage (p=0.018), tumor differentiation (p=0.014), parametrial invasion (p=0.024), lymphnode or hematogenous metastasis (p=0.005 or 0.019), but not other clinicopathological factors. Patients with high Aurora-A expression had a poorer disease-free survival and overall survival rates than patients with low Aurora-A expression. Multivariate analysis showed that high Aurora-A mRNA expression was an independent prognostic factor (risk ratio: 2.88; p=0.005).
Aurora-A might be used as a prognostic marker for cervical carcinoma patients.
Aurora-A是丝氨酸/苏氨酸激酶家族的一个新成员，据报道与肿瘤发生相关。我们的目的是研究Aurora-A的表达是否与宫颈癌患者的临床病理因素及预后相关。
设计/研究地点：回顾性研究。
1996年至2002年间的74例宫颈癌患者。
采用逆转录-聚合酶链反应和蛋白质印迹分析检测74例宫颈癌患者的宫颈癌细胞以及配对的癌组织和相应的非癌组织中Aurora-A基因的表达。还通过免疫组织化学法测定组织中Aurora-A蛋白的表达。通过统计学分析评估Aurora-A表达与患者临床因素及预后的关系。
宫颈癌细胞中Aurora-A mRNA和蛋白的表达显著高于正常宫颈上皮细胞（p<0.05）。癌组织中Aurora-A mRNA的表达显著高于相应的非癌组织（p<0.001）。免疫化学检测显示肿瘤组织中Aurora-A蛋白的表达也增加。Aurora-A转录本表达与国际妇产科联盟（FIGO）分期（p=0.018）、肿瘤分化（p=0.014）、宫旁浸润（p=0.024）、淋巴结或血行转移（p=0.005或0.019）相关，但与其他临床病理因素无关。Aurora-A高表达患者的无病生存率和总生存率低于Aurora-A低表达患者。多因素分析显示，Aurora-A mRNA高表达是一个独立的预后因素（风险比：2.88；p=0.005）。
Aurora-A可能作为宫颈癌患者的预后标志物。
